section name header

Pronunciation ⬇

foss-foe-MYE-sin

Classifications ⬆ ⬇

Therapeutic Classification: anti-infectives

Indications ⬆ ⬇

REMS


Action ⬆ ⬇

  • Inactivates an enzyme crucial for bacterial cell wall synthesis.
  • Decreases adherence of bacteria to uroepithelial cells.
Therapeutic effects:
  • Bactericidal action against susceptible bacteria.

Spectrum:

Pharmacokinetics ⬆ ⬇

Absorption: Rapidly absorbed and converted to fosfomycin, its active component, resulting in 37% bioavailability.

Distribution: Distributes to kidneys and bladder wall; crosses the placenta.

Metabolism/Excretion: Excreted unchanged in urine (38%) and feces (18%).

Half-Life: 5.7 hr.

Time/Action Profile ⬆ ⬇

(bactericidal urine levels‡)
ROUTEONSETPEAKDURATION
POrapid2–4 hrunknown

‡Symptoms may take 24–48 hr to subside.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

Canadian Brand Names ⬆ ⬇

Monurol

Code ⬆

NDC Code